Pfizer to Invest $500 Million in Gene Therapy Manufacturing Facility in North Carolina

Pfizer said it will invest $500 million in the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina, part of $5 billion the company is investing in capital projects in the United States over the next few years.

Photo: Mike McDermott, president of Pfizer Global Supply

This gene therapy manufacturing facility will support Pfizer’s continuing investment in gene therapy research and development. It will expand the company’s presence in North Carolina, where there are currently more than 3,600 Pfizer employees, and add 300 new jobs. Pfizer’s Sanford facility also manufactures components for the company’s vaccine portfolio.

Pfizer is expanding its end-to-end capabilities in gene therapy in North Carolina by investing in facilities focused on all stages of research, development, and manufacturing. The company said its existing and new investment in Sanford to manufacture gene therapies, is designed to result in a high-quality, efficient supply of gene therapies at clinical- and commercial-scale.

“This investment will further strengthen Pfizer’s leadership in gene therapy manufacturing technology,” said Mike McDermott, president of Pfizer Global Supply.

Author: Rare Daily Staff